Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.71)
# 758
Out of 4,988 analysts
436
Total ratings
48.9%
Success rate
13.1%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DFTX Definium Therapeutics | Reiterated: Buy | $64 → $78 | $38.81 | +100.98% | 21 | Sep 15, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $15.19 | +31.67% | 27 | Sep 10, 2026 | |
| ACAD ACADIA Pharmaceuticals | Reiterated: Buy | $36 | $27.29 | +31.92% | 55 | Sep 3, 2026 | |
| BHVN Biohaven | Reiterated: Buy | $21 | $13.62 | +54.19% | 6 | Aug 28, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $17 | $1.14 | +1,391.23% | 12 | Aug 18, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $27 → $18 | $2.43 | +640.74% | 21 | Aug 12, 2026 | |
| STOK Stoke Therapeutics | Reiterated: Buy | $58 | $28.43 | +104.01% | 18 | Aug 12, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $3.09 | +288.35% | 41 | Aug 12, 2026 | |
| ZVRA Zevra Therapeutics | Reiterated: Buy | $20 | $11.61 | +72.27% | 20 | Aug 11, 2026 | |
| GHRS GH Research | Reiterated: Buy | $39 | $28.26 | +38.00% | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $210 | $146.23 | +43.61% | 42 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $245 → $248 | $215.50 | +15.08% | 84 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $24 | $10.92 | +119.78% | 3 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $4.35 | +1,049.43% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $1.63 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $75 → $12 | $29.48 | n/a | 12 | Jan 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $31.80 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $38.98 | n/a | 9 | Jan 31, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $16.95 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $18.71 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $13.56 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $193.70 | $7.92 | n/a | 7 | Dec 18, 2015 |
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $64 → $78
Current: $38.81
Upside: +100.98%
COMPASS Pathways
Sep 10, 2026
Reiterated: Buy
Price Target: $20
Current: $15.19
Upside: +31.67%
ACADIA Pharmaceuticals
Sep 3, 2026
Reiterated: Buy
Price Target: $36
Current: $27.29
Upside: +31.92%
Biohaven
Aug 28, 2026
Reiterated: Buy
Price Target: $21
Current: $13.62
Upside: +54.19%
Annovis Bio
Aug 18, 2026
Reiterated: Buy
Price Target: $17
Current: $1.14
Upside: +1,391.23%
CervoMed
Aug 12, 2026
Reiterated: Buy
Price Target: $27 → $18
Current: $2.43
Upside: +640.74%
Stoke Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $58
Current: $28.43
Upside: +104.01%
Voyager Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $12
Current: $3.09
Upside: +288.35%
Zevra Therapeutics
Aug 11, 2026
Reiterated: Buy
Price Target: $20
Current: $11.61
Upside: +72.27%
GH Research
Aug 6, 2026
Reiterated: Buy
Price Target: $39
Current: $28.26
Upside: +38.00%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $210
Current: $146.23
Upside: +43.61%
Jul 30, 2026
Reiterated: Buy
Price Target: $245 → $248
Current: $215.50
Upside: +15.08%
Jul 27, 2026
Reiterated: Buy
Price Target: $35 → $24
Current: $10.92
Upside: +119.78%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $4.35
Upside: +1,049.43%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $1.63
Upside: n/a
Jan 28, 2022
Downgraded: Hold
Price Target: $75 → $12
Current: $29.48
Upside: n/a
Apr 9, 2018
Reiterated: Hold
Price Target: n/a
Current: $31.80
Upside: n/a
Jan 31, 2017
Upgraded: Buy
Price Target: n/a
Current: $38.98
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $16.95
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $18.71
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $13.56
Upside: n/a
Dec 18, 2015
Reiterated: Buy
Price Target: $193.70
Current: $7.92
Upside: n/a